Medtronic plc (MDT) — SEC Filings

Latest SEC filings for Medtronic plc (MDT), explained in plain English.

Sentiment Overview: 2 bullish, 29 neutral, 2 mixed

Recent Filings (33)

• Medtronic Q2 Sales Jump 6.6%, Net Income Up 8.2% Amid Diabetes Spinoff Plans — 10-Q · 2025-11-25T00:00:00.000Z [bullish] Risk: medium
  Medtronic plc reported a robust financial performance for the three and six months ended October 24, 2025. Net sales for the three-month period increased by 6.6
• 8-K Filing — 8-K · 2025-11-18T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-11-03T00:00:00.000Z [neutral]
• Medtronic plc Files 8-K with Corporate Updates and Debt Notes — 8-K · 2025-10-21T00:00:00.000Z [neutral] Risk: low
  On October 16, 2025, Medtronic plc filed an 8-K report detailing several items, including amendments to its articles of incorporation or bylaws, submission of m
• Medtronic plc Files 8-K: Material Agreement Details — 8-K · 2025-09-29T00:00:00.000Z [neutral] Risk: medium
  On September 29, 2025, Medtronic plc filed an 8-K detailing a material definitive agreement. The filing also includes other events and financial statements/exhi
• Medtronic Senior Notes Mature — 8-K · 2025-09-16T00:00:00.000Z [neutral] Risk: low
  On September 15, 2025, Medtronic plc filed an 8-K report detailing the maturity of its senior notes. Specifically, the $0.000 Senior Notes due 2025 and the $2.6
• Medtronic Sales Jump 8.4%, Diabetes Spinoff Looms — 10-Q · 2025-08-26T00:00:00.000Z [mixed] Risk: medium
  Medtronic plc reported net sales of $8,578 million for the three months ended July 25, 2025, an increase of 8.4% from $7,915 million in the prior-year period. N
• Medtronic Hits Record $33.5B Revenue, Eyes Strategic Capital Restructuring — DEF 14A · 2025-08-25T00:00:00.000Z [mixed] Risk: medium
  Medtronic plc reported record revenue of $33.5 billion for fiscal year 2025, marking a 3.6% increase as reported and 4.9% organic growth, which was at the upper
• Medtronic 8-K: Operations, Personnel Changes, Financials — 8-K · 2025-08-19T00:00:00.000Z [neutral] Risk: low
  Medtronic plc filed an 8-K on August 19, 2025, reporting on its results of operations and financial condition as of August 18, 2025. The filing also disclosed t
• Medtronic CFO Departs; Ishrak Takes Board Chair — 8-K · 2025-06-23T00:00:00.000Z [neutral] Risk: medium
  On June 18, 2025, Medtronic plc announced the departure of its Chief Financial Officer, Karen Parkhill, effective July 19, 2025. The company also announced the
• Medtronic Posts Strong FY25 Results, Revenue Up 4.5% to $32.3B — 10-K · 2025-06-20T00:00:00.000Z [bullish] Risk: medium
  Medtronic plc reported a robust fiscal year ending April 25, 2025, with revenue reaching $32.3 billion, marking a 4.5% increase from the previous fiscal year's
• Medtronic plc Files 8-K: Operations, Personnel, and Financials — 8-K · 2025-05-21T00:00:00.000Z [neutral] Risk: low
  On May 21, 2025, Medtronic plc filed an 8-K report detailing several key events. The filing includes information on the company's results of operations and fina
• Medtronic Director Departs, New Officers Elected — 8-K · 2025-03-17T00:00:00.000Z [neutral] Risk: low
  Medtronic plc announced on March 12, 2025, the departure of director Michael J. Minnick. The company also elected new directors and approved compensatory arrang
• Medtronic Q3 FY25 10-Q Filed — 10-Q · 2025-02-25T00:00:00.000Z [neutral] Risk: low
  Medtronic plc filed its 10-Q for the period ending January 24, 2025, reporting on its financial performance for the third quarter of fiscal year 2025. The filin
• Medtronic plc Files 8-K on Financial Condition — 8-K · 2025-02-18T00:00:00.000Z [neutral] Risk: low
  On February 18, 2025, Medtronic plc filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various
• Medtronic PLC Files 8-K: Director Changes and Officer Compensation — 8-K · 2025-01-21T00:00:00.000Z [neutral] Risk: low
  On January 17, 2025, Medtronic plc filed an 8-K report detailing the departure of a director and the election of a new director. The filing also disclosed compe
• Medtronic plc Files 10-Q for Q2 2025 — 10-Q · 2024-11-26T00:00:00.000Z [neutral] Risk: low
  Medtronic plc filed its 10-Q for the period ending October 25, 2024, reporting on its financial performance. The filing details various financial instruments an
• Medtronic plc Files 8-K on Financials and Senior Notes — 8-K · 2024-11-19T00:00:00.000Z [neutral] Risk: low
  On November 19, 2024, Medtronic plc filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various
• Medtronic plc Files 8-K on Shareholder Votes and Debt — 8-K · 2024-10-21T00:00:00.000Z [neutral] Risk: low
  On October 17, 2024, Medtronic plc filed an 8-K to report the submission of matters to a vote of security holders and financial statements. The filing also deta
• Medtronic plc Files Q1 FY25 10-Q Report — 10-Q · 2024-08-27T00:00:00.000Z [neutral] Risk: low
  Medtronic plc filed its 10-Q for the period ending July 26, 2024. The filing covers the first quarter of fiscal year 2025. Key financial details and operational
• Medtronic plc Files 8-K on Financials — 8-K · 2024-08-20T00:00:00.000Z [neutral] Risk: low
  On August 20, 2024, Medtronic plc filed an 8-K to report on its results of operations and financial condition. The filing includes financial statements and exhi
• Medtronic Updates Interim CFO Compensation — 8-K/A · 2024-08-16T00:00:00.000Z [neutral] Risk: low
  Medtronic plc filed an 8-K/A on August 16, 2024, to update a prior disclosure regarding compensation arrangements for its interim Chief Financial Officer (CFO).
• DEF 14A Filing — DEF 14A · 2024-08-09T00:00:00.000Z [neutral]
• Medtronic Appoints New Director Robert L. Lerman — 8-K · 2024-06-26T00:00:00.000Z [neutral] Risk: low
  On June 21, 2024, Medtronic plc announced the appointment of Robert L. Lerman as a new independent director to its Board of Directors, effective immediately. Le
• Medtronic plc Files 2024 Annual Report — 10-K · 2024-06-20T00:00:00.000Z [neutral] Risk: medium
  Medtronic plc filed its 10-K for the fiscal year ending April 26, 2024, reporting on its financial performance and business operations. The company, headquarter
• Medtronic Announces Executive & Board Changes — 8-K · 2024-06-04T00:00:00.000Z [neutral] Risk: low
  Medtronic plc announced on June 4, 2024, changes in its executive team and board of directors, effective June 1, 2024. Specifically, Robert L. Taiclet has been
• Medtronic plc Files 8-K: Material Definitive Agreement — 8-K · 2024-06-03T00:00:00.000Z [neutral] Risk: medium
  On June 3, 2024, Medtronic plc filed an 8-K to disclose the entry into a material definitive agreement. The filing also includes information related to Regulati
• Medtronic plc Files 8-K on Financials — 8-K · 2024-05-23T00:00:00.000Z [neutral] Risk: low
  On May 23, 2024, Medtronic plc filed an 8-K report detailing its financial condition and results of operations. The filing includes various exhibits related to
• Medtronic Details Senior Notes in Q3 2024 10-Q Filing — 10-Q · 2024-02-27T00:00:00.000Z [neutral] Risk: medium
  Medtronic plc filed its 10-Q for the period ending January 26, 2024, on February 27, 2024. The filing details various senior notes issued by the company, with m
• Medtronic 8-K Details Financials, Officer Changes, and Debt Structure — 8-K · 2024-02-20T00:00:00.000Z [neutral] Risk: low
  Medtronic plc filed an 8-K on February 20, 2024, reporting its financial condition and results of operations as of February 13, 2024. The filing also detailed c
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• BlackRock Amends Medtronic Stake, Signals Continued Confidence — SC 13G/A · 2024-02-12T00:00:00.000Z [neutral] Risk: low
  BlackRock Inc. filed an amended SC 13G/A on February 12, 2024, disclosing its ownership in Medtronic plc as of December 31, 2023. This filing, Amendment No. 7,